Annual Report 2005 - Boehringer Ingelheim

Animal Health
Our Animal Health division celebrated its 50th anniversary in 2005.
While this makes Boehringer Ingelheim one of the long-established companies
in this industry, it stands out as one of the most innovative and dynamic.
The anniversary year saw generally very satisfactory business development.
Sales rose by 8 % to around EUR 360 million in local currency. Our focus
in 2005 continued to be on the core segments livestock vaccines and chronic
diseases in companion animals and on optimisation of organisational
and marketing structures. This further consolidated our position among the
top 10 leading animal health companies in the world, giving us a global market
share of 3 %.
Regional differences
Growth in 2005 varied greatly from one region to
another. Once again, Europe, the growth engine
behind the Animal Health division, posted excellent
business development in the market with an
7 % increase in sales. The NAFTA region posted
sound growth of 9 %, but the year was marked by
special factors, such as the sale of the antibiotic
denagard® to Novartis. Asia also had a successful
year. Sales in China and Thailand more than
doubled, while the registration of ingelvac® prrs
in these countries paved the way for continued
strong growth. In Japan, the restructuring process,
aimed at streamlining the product portfolio and
concentrating on our core segments, is practically
complete. The launch of our porcine vaccine range
in Latin America and Eastern Europe is currently
being prepared.
Food-producing animals
Swine
The key event in the swine segment in 2005 was
the pan-European launch in Barcelona in October
2005 of enterisol® ileitis, the first and only
vaccine in the world for the widespread dis-
ease ileitis that is associated with diar-
rhoea. Our experience in practice to date
has been extraordinarily positive. In the
USA, every third pig was vaccinated
against ileitis in 2005, while control of
the disease was established as an essential
element of professional healthcare
Boehringer Ingelheim A n n u A l R e p o R t 2 0 0 5
management of pigs. In Germany, some produc-
ers’ associations have already declared the use of
the oral vaccine to be mandatory, only one year
after launch. enterisol® ileitis is thus well on
the way to becoming another of Animal Health’s
top products.
It is noteworthy that we received marketing
authorisation for enterisol® ileitis in Australia.
Not only is this the first Boehringer Ingelheim
vaccine to be introduced in Australia, but it is also
the first imported modified live vaccine to be given
marketing authorisation there.
Our flagship product ingelvac® prrs showed
extraordinary development, particularly in South
Korea where sales doubled. Our best-selling
vaccine is now also available in China, the largest
swine market in the world, allowing us to
consolidate further our No. 1 position there among
the international suppliers of porcine vaccines.
ingelvac® m. hyo also posted strong growth. This
enabled our young company in Thailand to
become market leader in this indication in a very
short time. Excellent results were also achieved in
France where ingelvac® m. hyo improved
by 36 % in a flat market, thus securing a
market share of 31 %.
On the whole, 2005 saw excellent progress
with our porcine vaccines, one of our core
target segments, putting us well on the way
to becoming global market leader.